Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Geranylated flavanone tomentodiplacone B inhibits proliferation of human monocytic leukaemia (THP-1) cells

P. Kollár, T. Bárta, V. Závalová, K. Smejkal, A. Hampl,

. 2011 ; 162 (7) : 1534-41.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12027909

BACKGROUND AND PURPOSE: Paulownia tomentosa is a rich source of geranylated flavanones, some of which we have previously shown to have cytotoxic activity. To identify members of this class of compounds with cytostatic effects, we assessed the effects of the geranylated flavanone tomentodiplacone B (TOM B) on cell cycle progression and cell cycle regulatory pathways of THP-1 human monocytic leukaemia cells. EXPERIMENTAL APPROACH: Cell viability was measured by dye exclusion and proliferation by WST-1 assays; cell cycle was monitored by flow cytometry. Regulatory proteins were assessed by immunoprecipitation and kinase assays, and Western blotting. KEY RESULTS: Tomentodiplacone B had no effect during the first 24 h of cell growth at concentrations between 1 and 2.5 µM, but inhibited cell growth in a dose-dependent manner at concentrations of 5 µM or higher. Growth inhibition during the first 24 h of exposure to TOM B was not accompanied by cytotoxicity as cells were accumulated in G1 phase dose-dependently. This G1 phase accumulation was associated with down-regulation of cyclin-dependent kinase 2 activity and also protein levels of cyclins E1 and A2. However, key stress-related molecules (γ-H2AX, p53 and p21) were not induced, suggesting that TOM B acts by directly inhibiting the cyclin-dependent kinase 2 signalling pathway rather than initiating DNA damage or cellular stress. CONCLUSIONS AND IMPLICATIONS: Our study provides the first evidence that TOM B directly inhibits proliferation of human monocytic leukaemia cells, and thus is a potential anticancer agent, preventing leukaemia cells from progressing from G1 phase into DNA synthesis.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12027909
003      
CZ-PrNML
005      
20121206122857.0
007      
ta
008      
120817s2011 enk f 000 0#eng||
009      
AR
024    7_
$a 10.1111/j.1476-5381.2010.01171.x $2 doi
035    __
$a (PubMed)21175584
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Kollár, Peter $u Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic. kollarp@vfu.cz
245    10
$a Geranylated flavanone tomentodiplacone B inhibits proliferation of human monocytic leukaemia (THP-1) cells / $c P. Kollár, T. Bárta, V. Závalová, K. Smejkal, A. Hampl,
520    9_
$a BACKGROUND AND PURPOSE: Paulownia tomentosa is a rich source of geranylated flavanones, some of which we have previously shown to have cytotoxic activity. To identify members of this class of compounds with cytostatic effects, we assessed the effects of the geranylated flavanone tomentodiplacone B (TOM B) on cell cycle progression and cell cycle regulatory pathways of THP-1 human monocytic leukaemia cells. EXPERIMENTAL APPROACH: Cell viability was measured by dye exclusion and proliferation by WST-1 assays; cell cycle was monitored by flow cytometry. Regulatory proteins were assessed by immunoprecipitation and kinase assays, and Western blotting. KEY RESULTS: Tomentodiplacone B had no effect during the first 24 h of cell growth at concentrations between 1 and 2.5 µM, but inhibited cell growth in a dose-dependent manner at concentrations of 5 µM or higher. Growth inhibition during the first 24 h of exposure to TOM B was not accompanied by cytotoxicity as cells were accumulated in G1 phase dose-dependently. This G1 phase accumulation was associated with down-regulation of cyclin-dependent kinase 2 activity and also protein levels of cyclins E1 and A2. However, key stress-related molecules (γ-H2AX, p53 and p21) were not induced, suggesting that TOM B acts by directly inhibiting the cyclin-dependent kinase 2 signalling pathway rather than initiating DNA damage or cellular stress. CONCLUSIONS AND IMPLICATIONS: Our study provides the first evidence that TOM B directly inhibits proliferation of human monocytic leukaemia cells, and thus is a potential anticancer agent, preventing leukaemia cells from progressing from G1 phase into DNA synthesis.
650    _2
$a antikarcinogenní látky $x farmakologie $7 D016588
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a proliferace buněk $x účinky léků $7 D049109
650    _2
$a cyklin D $x metabolismus $7 D056741
650    _2
$a cyklin-dependentní kinasa 2 $x antagonisté a inhibitory $x biosyntéza $x metabolismus $7 D051357
650    _2
$a cykliny $x metabolismus $7 D016213
650    _2
$a down regulace $x účinky léků $7 D015536
650    _2
$a flavanony $x farmakologie $7 D044950
650    _2
$a G1 fáze $x účinky léků $7 D016193
650    _2
$a lidé $7 D006801
650    _2
$a akutní monocytární leukemie $7 D007948
650    _2
$a monocyty $x cytologie $x účinky léků $x metabolismus $7 D009000
650    _2
$a monoterpeny $x farmakologie $7 D039821
650    _2
$a signální transdukce $x účinky léků $7 D015398
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Bárta, Tomáš
700    1_
$a Závalová, Veronika
700    1_
$a Smejkal, Karel
700    1_
$a Hampl, Aleš
773    0_
$w MED00009383 $t British journal of pharmacology $x 1476-5381 $g Roč. 162, č. 7 (2011), s. 1534-41
856    41
$u https://pubmed.ncbi.nlm.nih.gov/21175584 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m
990    __
$a 20120817 $b ABA008
991    __
$a 20121206122930 $b ABA008
999    __
$a ok $b bmc $g 949951 $s 785255
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 162 $c 7 $d 1534-41 $i 1476-5381 $m British journal of pharmacology $n Br J Pharmacol $x MED00009383
LZP    __
$a Pubmed-20120817/11/03

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...